Completes BPA Worldwide Initial Business Publication Audit
SHELTON, CT, 10/5/20 – Oncolytics Today has completed its BPA Worldwide business publication audit.
Glenn J. Hansen, BPA Worldwide President, praised Oncolytics Today for voluntarily opening its records to independent verification and documentation of its circulation data.
Hansen pointed out that the audit facilitates the buying and selling of advertising space. A BPA Worldwide report provides advertisers and agencies with assurance that what they choose to invest in does, in fact, reach target audiences for specific ads. The BPA Worldwide audit also helps media companies by documenting the quality of their audiences.
Copies of the initial BPA Worldwide audit report for Oncolytics Today are available from BPA Worldwide or the publisher.
Oncolytics Today will be issuing semi-annual Brand Reports.
BPA Worldwide conducts its circulation audits on an annual basis following accepted auditing procedures. In addition to verifying exact counts of recipients, BPA Worldwide also documents that they are qualified in the markets served by the publications.
View the full Press Release HERE.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamide (40.4 months) than with placebo (18.4 months). The data for the analysis of overall survival were immature at the time of the primary analysis. Read the full article HERE or download HERE.
CAMBRIDGE, Mass., September 4, 2020 – Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved GAVRETO™ (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. The approval is based on data from the Phase 1/2 ARROW clinical trial, which showed efficacy for GAVRETO in patients with RET fusion-positive NSCLC with or without prior therapy, and regardless of RET fusion partner or central nervous system involvement. Under Blueprint Medicines’ collaboration with Roche, Blueprint Medicines and Genentech, a member of the Roche Group, will co-commercialize GAVRETO in the U.S. GAVRETO is a once-daily oral RET-targeted therapy developed by Blueprint Medicines. It is designed to selectively and potently inhibit RET alterations that drive many cancer types, including approximately 1 to 2 percent of patients with NSCLC. Currently, RET is one of seven NSCLC biomarkers that can be targeted with an FDA-approved therapy. See the full Press Release HERE
To view GAVRETO’s product website, please visit www.GAVRETOHCP.com
To review the full Prescribing Information for GAVRETO, please click https://www.blueprintmedicines.com/uspi/GAVRETO.pdf
The industry-leading continuing pharmacy education provider becomes sole provider for association’s three major meetings through 2021
(CRANBURY, N.J. – August 23, 2020) – PTCE proudly announces it is now the exclusive continuing education (CE) provider for the National Community Oncology Dispensing Association, Inc. (NCODA) 2020-2021 meetings.
See Full Press Release here
On June 18, 2020, the Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.), an EZH2 inhibitor, for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. Read more HERE